Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies?
Author:
- 1 March 2014
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (5) , 1064-1066
Abstract
Cytotoxic drugs may have specific effects on oncogenes and their downstream targets. Increase of cancer cell sensitivity due to repression of an oncogene downstream target can be specifically addressed by combined precision chemotherapy, increasing the therapeutic index of chemotherapy and overcoming resistance to highly selective targeted therapies.Keywords
All Related Versions
This publication has 10 references indexed in Scilit:
- Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell GrowthClinical Cancer Research, 2014
- Emerging patterns of somatic mutations in cancerNature Reviews Genetics, 2013
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Pharmacotherapeutic Management of Pediatric GliomasPediatric Drugs, 2012
- Prospects and challenges for the development of new therapies for Ewing sarcomaPharmacology & Therapeutics, 2012
- Targeted Therapeutics in Treatment of Children and Young Adults with Solid Tumors: an Expert Survey and Review of the LiteratureKlinische Padiatrie, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Primed for resistanceNature, 2012
- Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput ScreeningJNCI: Journal of the National Cancer Institute, 2011
- High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT)Critical Reviews in Oncology/Hematology, 2002